Biotechs That Could Break from the Pack

Merrill Lynch's Eric Ende pinpoints four with accelerating earnings and improving fundamentals: Amgen, MedImmune, Gilead, and NPS

By Gene Marcial

To continue reading this article you must be a Bloomberg Professional Service Subscriber.